Cocrystal Pharma, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held on June 8, 2023. Cocrystal Pharma, Inc. is a Delaware corporation with its principal executive offices in Bothell, WA, and its common stock trades on The Nasdaq Capital Market under the symbol COCP.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on three primary proposals. All proposals were approved, rendering the fourth proposal regarding adjournment moot.
- Proposal 1 (Election of Directors): Six nominees were elected to the Board of Directors for a one-year term. All nominees received a majority of votes cast.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of Weinberg & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Proposal 3 (Say-on-Pay): Stockholders approved the non-binding advisory vote on executive compensation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific vote counts for Director Richard C. Pfenniger, Jr., who received the highest number of "Votes Withheld" (856,195) among the nominees.
- Confirm the total number of shares represented at the meeting by aggregating votes for, against, withheld, and broker non-votes.
- Note that the report was signed by James Martin in his capacity as Co-Interim Chief Executive Officer and Chief Financial Officer.
- Review the definitive proxy statement filed on April 28, 2023, for detailed background on the proposals and director biographies.